Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements (Details Textual)

v3.5.0.2
Note 5 - Fair Value Measurements (Details Textual) - Asuragen and Redpath [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2016
Business Combination, Contingent Cash Consideration, Deferred Payments   $ 4.6
Business Combination, Contingent Cash Consideration, Revenue Based Payments $ (0.3) 13.9
Business Combination Contingent Cash Consideration Deferred Payments, Net Increase (Decrease) in Fair Value   0.4
Business Combination Contingent Cash Consideration Deferred Payments, Increase (Decrease) in Fair Value   $ 0.7